Clinical trials
Dermatitis clinical trials
Below are recruiting dermatitis clinical trials, each written for real people, not researchers. We’re tracking 221 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07800104RecruitingPhase 1
Study of a new pill for moderate-to-severe eczema
This trial tests an experimental medicine called QX-4533. The study has two parts: one tests the drug in healthy volunteers, and the other tests it in people with moderate-to-severe atopic dermatitis (a type of eczema) that hasn't responded well to standard creams. The goal is to see if the drug is safe and how well it works.
Shanghai, Shanghai MunicipalityAges 1.5 years–65 years - NCT05098821Recruiting
Study factors that affect eczema control on dupilumab
This trial studies why eczema (“atopic dermatitis”) varies in severity even when people receive the medicine dupilumab. It may help doctors better predict who responds well and how to monitor treatment.
BerlinAges 18–75 - NCT07767253RecruitingPhase 3
New injectable medicine for children with moderate to severe eczema
This study tests a new medicine (called 611) given as an injection to children with moderate-to-severe eczema that hasn't improved with creams. The goal is to see if it can reduce itching and clear the rash.
Beijing, Beijing MunicipalityAges 2–11 - NCT07767461Recruiting
Patches to prevent skin irritation from diabetes devices in kids
This trial tests whether special patches placed under insulin pumps or glucose monitors can prevent or reduce skin irritation (contact dermatitis) in children and teens with type 1 diabetes.
CopenhagenAges 2–18 - NCT07754968Recruiting
Probiotic for formula-fed babies with colic
This study tests whether adding a probiotic called Bifidobacterium bifidum to formula can help reduce colic symptoms in babies who are not breastfed. It may also help if the baby has eczema (atopic dermatitis).
Roma, RMAges 1 week–5 months - NCT07746817RecruitingPhase 1
Study of a new drug for eczema
This study tests a new drug called BYN-001 in two groups: healthy people and people with moderate to severe eczema (atopic dermatitis). The goal is to see if the drug is safe and how well it works.
Melbourne, VictoriaAges 18–55 - NCT07746427Recruiting
Mindfulness program on a phone or tablet for teens with eczema
This study tests a digital mindfulness program to help teens manage their eczema. It looks at whether this approach can reduce symptoms and improve quality of life.
New York, New YorkAges 13–17 - NCT07734441RecruitingEarly Phase 1
Itraconazole vs Ketoconazole for Scalp Seborrheic Dermatitis
This study compares two treatments—itraconazole pills and ketoconazole shampoo—for moderate to severe dandruff on the scalp. It aims to find which works better for teens aged 14–17.
Chak Four Hundred Fifty-four, Punjab ProvinceAges 18–65 - NCT06362629Recruiting
Smartphone App for Managing Eczema
This trial tests a smartphone app designed to help people manage their atopic dermatitis (eczema). If you or your child has eczema and can use a smartphone, this app may help track symptoms and provide advice.
Chengdu, SichuanAges 1–75 - NCT07711418RecruitingPhase 3
A study of rezpegaldesleukin for teenagers and adults with moderate-to-severe eczema
This trial tests an investigational drug called rezpegaldesleukin for people aged 12 and older with moderate-to-severe atopic dermatitis (eczema) that hasn't improved enough with topical treatments. The goal is to see if it can safely reduce eczema symptoms.
Birmingham, AlabamaAges 12 years+ - NCT07690371RecruitingPhase 3
Study of rezpegaldesleukin for moderate to severe eczema
This study tests an experimental medicine (rezpegaldesleukin) for people with moderate to severe eczema. It aims to see if the drug can calm the immune system and improve skin symptoms when other treatments haven't worked.
Phoenix, ArizonaAges 12 years+ - NCT07660835RecruitingPhase 2
A study of nemolizumab for babies with eczema
This trial tests a medicine called nemolizumab for babies aged 6 to 23 months with moderate to severe eczema. The goal is to see if it reduces itching and improves skin symptoms.
San Antonio, TexasAges 6 months–1.9 years - NCT07643766RecruitingPhase 2
Testing ENV-294 for moderate-to-severe atopic dermatitis
This study tests whether a new medication called ENV-294 can help adults with moderate-to-severe atopic dermatitis (eczema) that hasn't responded well to other treatments. The trial will check if the drug reduces itching and skin inflammation safely.
Encinitas, CaliforniaAges 18 years+ - NCT07645820Recruiting
Testing a device to detect eczema flares early
This study tests a non-invasive home device called Nevisense Go that may help detect atopic dermatitis (eczema) flares before they become severe. You'll use the device at home, track your symptoms, and visit the clinic a few times to see if it helps predict when flares are coming.
Phoenix, ArizonaAges 12–89 - NCT07629778RecruitingPhase 1/Phase 2
HL-300 Ointment for Mild-to-Moderate Atopic Dermatitis
This study tests a new ointment (HL-300) designed to treat mild-to-moderate atopic dermatitis (a chronic skin condition causing itching and inflammation). You would apply it to affected skin areas to see if it safely reduces symptoms.
Hangzhou, ZhejiangAges 18–75 - NCT07604324RecruitingPhase 1
New Drug for Moderate to Severe Eczema Treatment
This study tests a new investigational drug called DCY636 to see if it can help people with moderate to severe atopic dermatitis (eczema) that hasn't improved with topical creams. The trial starts with safety testing in healthy volunteers, then moves to people with active eczema.
FukuokaAges 18–55 - NCT07598383RecruitingPhase 2
Gel treatment for mild-to-moderate atopic dermatitis
This study tests a new gel called VC005 to see if it safely reduces itching, redness, and irritation in people with atopic dermatitis (a chronic skin condition). You'll be randomly assigned to either the new gel or a placebo (inactive gel) and apply it to affected areas over several weeks.
Hangzhou, ZhejiangAges 18 years+ - NCT07600957Recruiting
Polarized Light Therapy to Ease Radiation Skin Damage
This trial tests whether a special type of light therapy can reduce skin damage and irritation that happens during radiation treatment for breast cancer. If it works, it could help patients feel more comfortable during and after their radiation therapy.
Banī SuwayfAges 35–55 - NCT07592585RecruitingPhase 3
Testing VC005 cream for mild-to-moderate eczema in teens and adults
This study tests a new medication called VC005 to treat atopic dermatitis (eczema)—a skin condition causing itching, redness, and inflammation. Researchers want to see if VC005 can safely reduce symptoms in people aged 12 and older with mild-to-moderate cases.
Nanjing, JiangsuAges 12 years+ - NCT07573735Recruiting
Blood markers and skin inflammation in atopic dermatitis
This study examines a specific blood marker (cfDNA-STING) that may help explain why atopic dermatitis develops. Researchers will compare this marker in people with and without atopic dermatitis to understand the condition better.
Nanjing, JiangsuAges 18 years+ - NCT03394417Recruiting
StrataXRT skin gel to prevent rash during head and neck radiation
This trial tests whether a medicated skin gel (StrataXRT) can better prevent painful skin rash (“acute dermatitis”) in people with head and neck cancer who receive chemotherapy and radiation at the same time. If you’re eligible, you may get the study skin product and help doctors find a safer, more comfortable way to protect the skin during treatment.
SingaporeAges 21–80 - NCT07560618RecruitingPhase 4
Testing a new cream for itch relief in atopic dermatitis
This study tests whether roflumilast cream (a new anti-inflammatory medication applied to the skin) can reduce the intense itching caused by atopic dermatitis (eczema). You'll track your itching daily using a smartphone app and visit the clinic to see if the cream helps over time.
Sacramento, CaliforniaAges 12 years+ - NCT07558668RecruitingPhase 1
Testing SYX-5219 for atopic dermatitis in healthy people and patients
This trial tests a new drug called SYX-5219 to see if it is safe and how the body handles it. Part 1 and 2 use healthy volunteers, while Part 3 tests it in people with moderate to severe atopic dermatitis (eczema). The goal is to understand if this drug might help treat eczema symptoms like itching and skin inflammation.
Arkansas City, ArkansasAges 18–65 - NCT07544862Recruiting
Stapokibart injection for atopic dermatitis in adults
This study tests a new injection medicine called Stapokibart for treating atopic dermatitis (a chronic skin condition causing itching and inflammation). Your doctor has already decided this medicine might help you before you joined the study.
Beijing, Beijing MunicipalityAges 18 years+
Hear when a new Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for dermatitis?
- Yes. Clin2 currently lists 221 recruiting dermatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a dermatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a dermatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.